Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension.

Clin Ophthalmol · 2026 · PMC13184553 · PMID 42164977

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In addition to these anatomic benefits, pegcetacoplan treatment also demonstrated functional benefit in a microperimetry analysis in subfoveal GA eyes, with significant reductions at 36 months in the overall formation of absolute scotomas with PM (26% reduction compared with sham crossover; p=0.0050), while PEOM did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.